Stock Analysis, Forecast and Trading Ideas

04:23am, Thursday, Jul 02, 2026

Abivax Stock Jumps as Underwriters Exercise Full Greenshoe Option, Raising Total Offering to $920M

Shares of Abivax climb nearly 6% following full exercise of underwriters' option to acquire additional shares, swelling the recent $800M equity raise to $920M and extending the company's cash runway into 2029 amid FDA NDA plans.

A

07:04am, Tuesday, Jun 30, 2026

Abivax Shares Surge 27% Following Promising Ulcerative Colitis Drug Trial Results

Abivax jumps 27% as its experimental ulcerative colitis drug shows strong remission rates in difficult-to-treat patients, with plans to file FDA application later this year.

A

06:29am, Tuesday, Jun 02, 2026

Abivax Shares Dive Over 30% Following Safety Concerns in Phase 3 Trial

Abivax stock plunged after Phase 3 trial results showed promising efficacy for obefazimod but revealed unexpected cancer cases at higher doses, stirring investor caution despite reassurances.

A

06:08am, Monday, Jan 12, 2026

Abivax Shares Rocket Amid Rumors of Eli Lilly's Billion-Euro Buyout Interest

Shares of Abivax (EPA: ABVX) leap over 23% following reports that Eli Lilly (NYSE: LLY) is eyeing a billion-euro acquisition, stirring chatter on a potential mega-deal in biotech.

A

Ticker: ABVX